Related Experiment Video
Updated: Jul 31, 2026

Use of the Operant Orofacial Pain Assessment Device (OPAD) to Measure Changes in Nociceptive Behavior
Published on: June 10, 2013
Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats
1Department of Anesthesiology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.
Abstract:
Morphine has been used in previous studies that investigate interactions between the spinal cord mu-opioid and N-methyl-D-aspartate (NMDA) receptors in mechanisms of antinociceptive tolerance. Although morphine acts primarily on the mu-receptor, it also activates other subtypes of opioid receptors. In the present study, the selective mu-opioid agonist, D-Ala2-N-Me-Phe4,Gly-ol5-enkephalin (DAMGO), was used to further test the hypothesis. Repeated intrathecal (i.t.) administration of 6 microg DAMGO (twice daily) in rats for 7 days resulted in an approximately 17-fold rightward shift of the cumulative dose-response curve (the tail-flick test) on Day 8 compared to that on Day 1. This rightward shift of the dose-response curve was prevented by the i.t. co-administration with DAMGO of the NMDA receptor antagonist MK-801 (10 = 5 > 2.5 >> 1.25 nmol > saline). Further, a lower dose range of MK-801 (2.5 > 1.25 nmol > 0.625 > 0.313 = saline) was effective to prevent the antinociceptive tolerance to a lower dose (1.5 microg) of DAMGO using the same i.t. administration regimen. Thus, the present results provide further evidence supporting a cellular and intracellular model of opioid tolerance involving interactions between the mu-opioid and the NMDA receptors in the spinal cord.
Insights
Spinal cord mu-opioid and N-methyl-D-aspartate (NMDA) receptor interactions contribute to antinociceptive tolerance. Blocking NMDA receptors with MK-801 prevented tolerance to the mu-opioid agonist DAMGO.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Morphine's interaction with spinal cord mu-opioid and N-methyl-D-aspartate (NMDA) receptors is implicated in antinociceptive tolerance.
- Morphine acts on mu-receptors but also other opioid receptor subtypes.
Purpose of the Study:
- To investigate the role of spinal cord mu-opioid and NMDA receptor interactions in antinociceptive tolerance.
- To test the hypothesis using a selective mu-opioid agonist, D-Ala2-N-Me-Phe4,Gly-ol5-enkephalin (DAMGO).
Main Methods:
- Repeated intrathecal (i.t.) administration of DAMGO (6 microg, twice daily for 7 days) in rats.
- Assessment of antinociceptive tolerance using the tail-flick test on Day 8.
- Co-administration of DAMGO with NMDA receptor antagonist MK-801 to evaluate prevention of tolerance.
Main Results:
- Repeated DAMGO administration induced a significant rightward shift (approx. 17-fold) in the dose-response curve, indicating antinociceptive tolerance.
- Co-administration of MK-801 with DAMGO effectively prevented this induced antinociceptive tolerance.
- A lower dose range of MK-801 also prevented tolerance to a lower dose of DAMGO.
Conclusions:
- The results support a model of opioid tolerance involving spinal cord interactions between mu-opioid and NMDA receptors.
- This highlights the cellular and intracellular mechanisms underlying opioid tolerance.
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids

